Cozart raises $4 million in the drugs-of-abuse race
This article was originally published in Clinica
Executive Summary
UK private diagnostic company Cozart plans to expand its R&D and boost sales and marketing in order to export to new territories, following the investment of £3.1 million ($4.3 million) raised in a recent private funding round.